



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	July 7, 2022 September 15, 2022, January 24, 2024, August 19, 2024

TEZSPIRE® (tezepelumab-ekko)

LENGTH OF AUTHORIZATION: One year

REVIEW CRITERIA:

- Patient must be ≥ 12 years of age; **AND**
- Must have a diagnosis of severe asthma; **AND**
- Prescribed by or in consultation with an allergist, pulmonologist, or immunologist; **AND**
- Patient has ongoing symptoms of asthma with a minimum three-month trial of an inhaled corticosteroid plus a long-acting beta 2 agonist (LABA) combination therapy; **AND**
- Tezspire will not be used in combination with other biologics (e.g., Fasenra, Nucala, Xolair, Dupixent, etc.).

CONTINUATION OF THERAPY:

- Initial approval criteria for therapy has been met at the time of initiation of therapy.
- Tezspire will not be used in combination with other biologics (e.g., Fasenra, Nucala, Xolair, Dupixent, etc.).
- Dosing is appropriate as per labeling or is supported by compendia.
- Treatment with Tezspire has resulted in clinical improvement as documented in progress notes by:
 - One or more of the following:
 - Decreased utilization of rescue medications; **OR**
 - Decreased frequency of exacerbations (defined as worsening of asthma that requires increase in inhaled corticosteroid dose or treatment with systemic corticosteroids); **OR**
 - Reduction in reported asthma-related symptoms, such as, but not limited to, wheezing, shortness of breath, coughing, fatigue, sleep disturbance, or asthmatic symptoms upon awakening.
- Continued use of inhaled corticosteroid plus LABA combination while on Tezspire therapy for asthma is documented.
- Patients should be periodically reassessed for the need to continue therapy based on the disease severity and/or the level of asthma control.

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as: 210 mg/1.91 mL (110 mg/mL) single-dose vial, single-dose pre-filled syringe, and single-dose pre-filled pen.